Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer

被引:1
|
作者
Zhou, Siyu [1 ]
Tao, Baian [1 ]
Guo, Yujie [1 ]
Gu, Jichun [1 ]
Li, Hengchao [1 ]
Zou, Caifeng [1 ]
Tang, Sichong [2 ]
Jiang, Shuheng [3 ]
Fu, Deliang [1 ]
Li, Ji [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Pancreat Surg, Shanghai 200040, Peoples R China
[2] Fudan Univ, Sch Med, Shanghai 200240, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med,State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China
关键词
Pancreatic cancer; Plasma proteome; Therapeutic target; Mendelian randomization; ABO BLOOD-GROUP; MENDELIAN RANDOMIZATION; CHONDROITIN SULFATE; CARDIOVASCULAR RISK; EPIDEMIOLOGY; POPULATION; MARKERS; EQTL;
D O I
10.1186/s12967-024-05363-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Deciphering the role of plasma proteins in pancreatic cancer (PC) susceptibility can aid in identifying novel targets for diagnosis and treatment.Methods We examined the relationship between genetically determined levels of plasma proteins and PC through a systemic proteome-wide Mendelian randomization (MR) analysis utilizing cis-pQTLs from multiple centers. Rigorous sensitivity analyses, colocalization, reverse MR, replications with varying instrumental variable selections and additional datasets, as well as subsequent meta-analysis, were utilized to confirm the robustness of significant findings. The causative effect of corresponding protein-coding genes' expression and their expression pattern in single-cell types were then investigated. Enrichment analysis, between-protein interaction and causation, knock-out mice models, and mediation analysis with established PC risk factors were applied to indicate the pathogenetic pathways. These candidate targets were ultimately prioritized upon druggability and potential side effects predicted by a phenome-wide MR.Results Twenty-one PC-related circulating proteins were identified in the exploratory phase with no evidence for horizontal pleiotropy or reverse causation. Of these, 11 were confirmed in a meta-analysis integrating external validations. The causality at a transcription level was repeated for neutrophil elastase, hydroxyacylglutathione hydrolase, lipase member N, protein disulfide-isomerase A5, xyloside xylosyltransferase 1. The carbohydrate sulfotransferase 11 and histo-blood group ABO system transferase exhibited high-support genetic colocalization evidence and were found to affect PC carcinogenesis partially through modulating body mass index and type 2 diabetes, respectively. Approved drugs have been established for eight candidate targets, which could potentially be repurposed for PC therapies. The phenome-wide investigation revealed 12 proteins associated with 51 non-PC traits, and interference on protein disulfide-isomerase A5 and cystatin-D would increase the risk of other malignancies.Conclusions By employing comprehensive methodologies, this study demonstrated a genetic predisposition linking 21 circulating proteins to PC risk. Our findings shed new light on the PC etiology and highlighted potential targets as priorities for future efforts in early diagnosis and therapeutic strategies of PC.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets
    Wen, Zhuofeng
    Liang, Weixuan
    Yang, Ziyang
    Liu, Junjie
    Yang, Jing
    Xu, Runge
    Lin, Keye
    Pan, Jia
    Chen, Zisheng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [2] Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
    Shi, Yingzhou
    Dong, Hang
    Sun, Shiwei
    Wu, Xiaoqin
    Fang, Jiansong
    Zhao, Jianbo
    Han, Junming
    Li, Zongyue
    Wu, Huixiao
    Liu, Luna
    Wu, Wanhong
    Tian, Yang
    Yuan, Guandou
    Fan, Xiude
    Xu, Chao
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 80 - 97
  • [3] ModulOmics: Integrating Multi-Omics Data to Identify Cancer Driver Modules
    Silverbush, Dana
    Cristea, Simona
    Yanovich, Gali
    Geiger, Tamar
    Beerenwinkel, Niko
    Sharan, Roded
    RESEARCH IN COMPUTATIONAL MOLECULAR BIOLOGY, RECOMB 2018, 2018, 10812 : 283 - 284
  • [4] Integrating multi-omics data to identify dysregulated modules in endometrial cancer
    Chen, Zhongli
    Liang, Biting
    Wu, Yingfu
    Liu, Quanzhong
    Zhang, Hongming
    Wu, Hao
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2022, 21 (04) : 310 - 324
  • [5] Potential therapeutic targets of Klebsiella pneumoniae: a multi-omics review perspective
    Ali, Sabeeha
    Alam, Manzar
    Hasan, Gulam Mustafa
    Hassan, Md Imtaiyaz
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2022, 21 (02) : 63 - 77
  • [6] Multi-Omics Reveals IBS Therapeutic Targets
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (06) : 1121 - 1121
  • [7] The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease
    Cisek, Katryna
    Krochmal, Magdalena
    Klein, Julie
    Mischak, Harald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (12) : 2003 - 2011
  • [8] Identification of therapeutic targets of gallbladder cancer using multi-omics approach
    Ali, Asgar
    Ahmad, Ejaj
    Verma, Renu
    Sahu, Parameswar
    Nimisha
    Srivastava, Siddharth
    Saluja, Sundeep Singh
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2023, 22 (02) : 109 - 122
  • [9] Correspondence to editorial on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets"
    Shi, Yingzhou
    Yuan, Guandou
    Fan, Xiude
    Xu, Chao
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [10] Reply to correspondence on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets"
    Rezaee-Zavareh, Mohammad Saeid
    Kim, Naomy
    Yang, Ju Dong
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)